...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cellular Physiology >Current Controversies in the Management of Myeloma Bone Disease
【24h】

Current Controversies in the Management of Myeloma Bone Disease

机译：目前的争议在骨髓瘤的管理骨骼疾病

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recent significant advances in the treatment of multiple myeloma have resulted in an improvement in median overall survival from 4.6 years, for patients diagnosed between 2001 and 2005, to 6.1 years, for those diagnosed between 2006 and 2010 (Kumar et al., 2014). However, myeloma bone lesions persist in the absence of active disease and continue to be frequent and significant causes of patient morbidity and contribute to mortality. While bisphosphonate therapy in combination with anti-myeloma therapy remains the cornerstone of skeletal disease management in myeloma, open questions regarding the optimal management of patients with myeloma bone disease remain. This article will address when to initiate and stop bone-targeted therapy in patients with monoclonal gammopathies, duration of bisphosphonate treatment in the era of more effective anti-myeloma treatment, the role of bone resorption markers in determining the dosing schedule for anti-resorptive therapy, risks and benefits of long term anti-resorptive therapy, and whether anti-resorptive therapies should be stopped to enhance the potential anabolic effects of proteasome antagonists and other anabolic agents. (C) 2016 Wiley Periodicals, Inc.
机译：最近的治疗的重要进展多发性骨髓瘤已经导致了一种进步总体生存中值从4.6年病人在2001年到2005年之间,至6.1年,确诊为2006年和2010年之间(Kumar et al ., 2014)。病变持续在缺乏活跃的疾病并继续频繁和重要病人发病率和导致的原因死亡率。结合anti-myeloma疗法仍然是骨骼疾病管理的基石关于最优骨髓瘤,开放式问题骨髓瘤骨病患者的管理依然存在。启动和停止bone-targeted治疗单克隆丙种球蛋白病的患者,持续时间二磷酸盐治疗的时代有效anti-myeloma治疗的作用骨吸收标记确定剂量时间表anti-resorptive治疗,风险和长期的好处anti-resorptive疗法,和anti-resorptive疗法是否应该停止提高潜在的合成代谢的影响蛋白酶体的拮抗剂和其他合成代谢代理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号